# Oritavancin for Treatment of Serious Cardiac Infections

> **NCT07550595** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kirby Institute** · enrollment: 20 (estimated)

## Conditions studied

- Infective Endocarditis
- Cardiac Device Infection
- Gram-positive Bacterial Infections

## Interventions

- **DRUG:** Oritavancin
- **DRUG:** Oritavancin

## Key facts

- **NCT ID:** NCT07550595
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550595, "Oritavancin for Treatment of Serious Cardiac Infections". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07550595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*